Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on X about a paper he co-authored with colleagues published in ESMO Open:
“Path CR with NACT + pembrolizumab (K522reg) in non-metastatic TNBC inflammatory breast cancer set at 31.7%.
Need for better patient selection and more active treatment options for this rare and aggressive breast cancer subtype.”
Title: Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
Authors:
You can read the full article in ESMO Open.
More posts featuring Antonio Giordano on OncoDaily.